KRAS and cancer: For example, a recent large study on GBC uncovered significantly mutated genes related to ERBB2, ERBB3, KRAS, PIK3CA and BRAF, and neoantigens from several mutated GBC genes including ELF3, ERBB2 and TP53 that were proven to activate T cells, therefore being potential candidate antigens for a therapeutic cancer vaccine.